Friday, September 24, 2021 3:02:57 PM
This is “much ado about nothing”. All of these assets are for the benefit of NWBO shareholders. NWBio own all of the Sawston equipment, and leasehold improvements in that facility, That includes all of the clean rooms. Cognate and Advent are only “a means to an end”. The primary reasons Cognate was started were:
(1) To help NWBio fulfill the FDA’s and Health Canada’s requirement to have licensed and approved GMP manufacturing capabilities to complete the DCVax-L Phase III clinical trial.
(2) Convince the FDA and Health Canada that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the US and Canada.
(3) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, including Big Pharma
The primary reasons Advent was started were:
(1) Convince the EMA and MHRA that NWBio would be able to produce enough DCVax-L, on a commercial scale, to justify regulatory approval of DCVax-L in the UK, Germany and the rest of the EU.
(2) Protect the DCVax-L and DCVax Direct patents and other IP from rivals, and potential rivals, in Europe including Big Pharma.
Both Cognate and Advent have served, and are continuing to serve their purpose. Both Cognate and Advent have created a lot of NWBO value and gains for NWBO shareholders. It is unfortunate that some NWBO shareholders don’t acknowledge or understand these facts.
I, personally prefer that NWBio continue to focus on becoming a high margin, highly profitable biotech, by focusing on exploiting and maximizing the worldwide value of the DCVax-L and DCVax Direct vaccine platform, that has the potential to treat all or most solid tumor cancers, both operable and inoperable.
I am not interested in NWBio focusing on a lower margin, more capital intensive and more labor intensive industry, like becoming a CDMO.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM